Arcellx, CAR T Therapy, CART DDBCMA, antigen receptor chimaricus, milvus tecta, multa myeloma
MILVUS et ARCELLX CONVENIENTIA AD CO-EVELOP ET CO COMMERCIUM NUPER SCAENA CLINICAL Cart-DDBCMA MULTIPLICA MYELOMA
SANTA MONICA, CALIF. & REDWOOD CIVITAS, CALIF.--(NEGOTIIS WIRE)-- Milvus, societas Galaad (NASDAQ: GILD), et Arcellx, Inc. nuntiatum global opportuna ..
SPHERA, Brexucabtagenes autoleucel, milvus tecta, Tecartus, ZUMA-3
Brexucabtagenum autoleucelum approbatur a FDA pro relapso vel refractorio B-cello praecursori acuto lymphoblastico leukemia
Octobris 2021 : Brexucabtagne autoleucel (Tecartus, Milvus Pharma, Inc.) approbata est ab Administratione Cibus et medicamentis adultis aegris relapsis vel refractoribus B-cell praecursoribus acutis leukemia lymphoblastica (ALL). In..
axicabtagen ciloleucel, Car - T Cell Lorem, CD19, folliculorum lymphoma, milvus tecta, durum folliculorum lymphoma, folliculorum portu lymphoma, Yescarta
FDA approbatione est firma dederit axicabtagene ciloleucel expediri vel praefracti folliculorum lymphoma.
Augusti 2021 : FDA axicabtagena ciloleucel dedit (Yescarta, Kite Pharma, Inc.) expeditum approbationem pro aegris adultis relapso vel refractorio lymphoma folliculari (FL) post duas vel plures lineas therapiae systemicae. Psalmus.